Chugai Pharmaceutical Co., Ltd. announced that it received from the Minister of Health, Labour and Welfare, a notification of orphan drug designation for human anti-human IL-6 receptor monoclonal antibody "tocilizumab," a drug under development for treatment of systemic scleroderma.
Systemic scleroderma is designated as an intractable disease, by the Ministry of Health, Labour and Welfare. It manifests skin hardening, and internal organs are affected associated with its progression. Its etiology is yet to be fully elucidated. Current therapeutic options are only symptomatic in nature, such as corticosteroids and immunosuppressants and no established treatment is in place that can alleviate signs and symptoms as a whole. A new therapeutic agent with improved efficacy has been long awaited.
Chugai has been engaged in clinical development of tocilizumab as a drug for systemic scleroderma, in cooperation with its strategic alliance partner, Roche. A Phase III placebo-controlled clinical trial "focuSSced" is now under way. In February 2015, the results of the previous study, a Phase II clinical trial "faSScinate" indicated the possibility of improved efficacy of tocilizumab compared to existing drugs. Based on this finding, tocilizumab has been designated as a "Breakthrough Therapy" by the U.S. Food and Drug Administration.
